Shire sells cancer drugs to Servier for $2.4B as Takeda circles

Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceu.....»»

Shire said on Monday it would consider returning proceeds from the sale to shareholders through a buyback and that further selective disposals of non-strategic assets were possible......»»

LONDON (Reuters) - Shire , the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical , is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion......»»

Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. T.....»»

Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters......»»

Takeda Pharmaceutical Co Ltd agreed to sell its dry eye drug to Swiss drugmaker Novartis AG for $3.4 billion and potential milestone payments of up to $1.9 billion, in the first divestment since its takeover of Britain's Shire......»»

Related Stocks: CMI, WPP, AXP, LOW, WTR, TAK, AAPL, CPB, ABB, SHPG, MKL, HBAN,.....»»

TOKYO/LONDON (Reuters) - Japan's Takeda Pharmaceutical nudged up its offer for Shire to 44.3 billion pounds ($62 billion) on Friday to try to persuade the rare-disease drugs specialist into talks after it rejected three previous proposals......»»

Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover......»»

Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover......»»

LONDON/TOKYO (Reuters) - Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry......»»

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , a Takeda spokesman said, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt......»»

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt......»»

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt......»»

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt. Julian Satterthwaite reports......»»

Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire , creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt......»»

Twenty years ago, Pfizer Inc. didn’t sell any drugs treating cancer. Now, it sells 17, including four that were approved in the U.S. at the end of last year, more than any other pharmaceutical company......»»

read more.....»»

read more.....»»

Cancer treatment has evolved from the use of chemotherapeutic anti-tumor drugs to targeted therapies to monoclonal antibodies to immunotherapies to new, personalized therapeutics. read more.....»»